
Gynecologic Cancer
Ovarian
10422: Abemaciclib and Olaparib for Recurrent Ovarian Cancer
10324: A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Now ETCTN wide
10433: Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors
10597: A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers
Uterine
10355: A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies (Escalation: HER2 positive advanced solid tumors; Expansion: HER2 positive uterine serous carcinoma)
10401: A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma